tradmap

NVAX Novavax Inc

$10.34 +0.19%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Novavax Inc (NVAX) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $1.7 billion. Shares last traded at $10.34, 13.6% below their 52-week high. Over the past year the stock is up 39.9%. Net profit margin is -22.1%, below the peer median of 5.3%. Revenue grew 64.7% year over year.

Market Cap
$1.7B
Shares Out
164.9M
EPS (TTM)
$5.64
P/E Ratio
1.83
P/S Ratio
1.52
P/B Ratio
Dividend / Share
Dividend Yield
52-Week High
$11.97
52-Week Low
$6.21
Volume
229,394
Avg Vol (3m)
263,222.556

Performance

1W
+14.19%
1M
+34.11%
3M
+1.67%
6M
+3.50%
YTD
+45.02%
1Y
+39.92%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
73.43
SMA (50)
$8.55
SMA (200)
$8.54
Price vs SMA50
+20.98%
Price vs SMA200
+21.10%
ATR (14)
$0.53

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$1.1B
Net Income
$-248M
Gross Margin
29.0%
Operating Margin
-20.8%
Net Margin
-22.1%
Return on Equity
129.9%
Return on Assets
-25.9%
Current Ratio
2.33
Debt / Equity
-1.53
Revenue Growth (YoY)
+64.7%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.38 2026-08-06
Q1 2026 $-0.06 2026-05-06
FY 2025 $2.58 2026-02-26
Q3 2025 $2.53 2025-11-06
Q2 2026 $3.55 2026-08-06
Q1 2026 $2.93 2026-05-06

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

NVAX vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
1.52 / 19.49 med
-92% discount
Net margin vs peers
-22.1% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.